MRK vs. AMGN, CORT, GILD, MRNA, VRTX, ABBV, BMY, JNJ, LLY, and PFE
Should you be buying Merck & Co., Inc. stock or one of its competitors? The main competitors of Merck & Co., Inc. include Amgen (AMGN), Corcept Therapeutics (CORT), Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Pfizer (PFE). These companies are all part of the "medical" sector.
Merck & Co., Inc. vs. Its Competitors
Merck & Co., Inc. (NYSE:MRK) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.
Merck & Co., Inc. has higher revenue and earnings than Amgen. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Merck & Co., Inc. has a net margin of 27.27% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Merck & Co., Inc.'s return on equity.
In the previous week, Merck & Co., Inc. had 16 more articles in the media than Amgen. MarketBeat recorded 73 mentions for Merck & Co., Inc. and 57 mentions for Amgen. Amgen's average media sentiment score of 1.25 beat Merck & Co., Inc.'s score of 1.22 indicating that Amgen is being referred to more favorably in the news media.
Merck & Co., Inc. has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
Merck & Co., Inc. pays an annual dividend of $3.24 per share and has a dividend yield of 3.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.1%. Merck & Co., Inc. pays out 47.2% of its earnings in the form of a dividend. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 14 consecutive years and Amgen has increased its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and lower payout ratio.
Merck & Co., Inc. currently has a consensus price target of $108.69, suggesting a potential upside of 28.14%. Amgen has a consensus price target of $307.27, suggesting a potential upside of 0.23%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than Amgen.
76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.8% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Merck & Co., Inc. beats Amgen on 10 of the 19 factors compared between the two stocks.
Get Merck & Co., Inc. News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Merck & Co., Inc. Competitors List
Related Companies and Tools
This page (NYSE:MRK) was last updated on 7/26/2025 by MarketBeat.com Staff